Micromet Inc (MITI)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
2110 RUTHERFORD CARLSBAD, CA 92008

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Micromet, Inc., a biopharmaceutical company, develops antibody-based products for cancer, inflammatory, and autoimmune diseases. Its products under clinical trials include MT103, a Phase I clinical trial product candidate for the treatment of patients with non-Hodgkins lymphoma; and Adecatumumab, a recombinant human monoclonal antibody that is under clinical Phase IIa status for metastatic breast cancer and other adenocarcinoma indications, and is being evaluated in clinical Phase Ib trials for treatment of metastatic breast cancer in combination with docetaxel. The company's preclinical development products include MT203 and MT204 human antibodies to treat various acute and chronic inflammatory diseases, including rheumatoid arthritis, asthma, psoriasis, and multiple sclerosis; EphA2, a cell surface membrane-associated receptor tyrosine kinase for the treatment of cancer; CEA, which is indicated for the treatment of tumors of epithelial origin, such as colorectal carcinoma, lung adenocarcinoma, mucinous ovarian carcinoma, and endometrial adenocarcinoma; MORAb28, a human IgM monoclonal antibody binding to an antigen that is identified as a cell-surface antigen present on human melanomas and tumors of neuroectodermal origin; and MT110, a molecule that combines binding specificities for EpCAM and for CD3 on T cells. Micromet's product pipeline also consists of D93, a humanized, anti-metastatic, and anti-angiogenic monoclonal antibody for treatment of patients with solid tumors. It has strategic collaborations with MedImmune, Inc. for MT103; Nycomed for development of anti-GM-CSF antibodies; and Merck Serono Biopharmaceuticals S.A. for adecatumumab.

View SEC Filings from MITI instead.

View recent insider trading info

Micromet Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding MITI (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MITI

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HALE DAVID F

  • Director
 No longer subject to file 2012-03-07 0

GRAU ULRICH M EVP AND COO

  • Officer
 No longer subject to file 2012-03-07 0

SLATTERY JOSEPH P

  • Director
 No longer subject to file 2012-03-07 0

CARTER MICHAEL G

  • Director
 No longer subject to file 2012-03-07 0

PHILLIPS BARCLAY A SVP, CFO

  • Officer
 No longer subject to file 2012-03-07 0

BERRIMAN JOHN E

  • Director
 No longer subject to file 2012-03-07 0

ITIN CHRISTIAN PRESIDENT AND CEO

  • Officer
 No longer subject to file 2012-03-07 0

BAEUERLE PATRICK SVP, CSO

  • Officer
 No longer subject to file 2012-03-07 0

HENNECKE JENS SVP, BUSINESS DEVELOPMENT

  • Officer
 No longer subject to file 2012-03-07 0

JOHANN PETER

  • Director
 No longer subject to file 2012-03-07 0

ALDER MATTHIAS SVP, GC AND SECRETARY

  • Officer
 No longer subject to file 2012-03-07 0

FAGERBERG JAN SVP, CHIEF MEDICAL OFFICER

  • Officer
 No longer subject to file 2012-03-07 0

LOBACKI JOSEPH M SVP & CHIEF COMMERCIAL OFFICER

  • Officer
 No longer subject to file 2012-03-07 0

AMGEN INC

ARMSTRONG ACQUISITION CORP.

  • 10% Owner
 No longer subject to file 2012-03-06 0

SCOTT DAVID J

  • Director
 0 2012-03-02 0

MCNAMEE BRIAN M

  • Director
 0 2012-03-02 0

SHARER KEVIN W

  • Director
 0 2012-03-02 0

BRADWAY ROBERT A

  • Director
 0 2012-03-02 0

PEACOCK JONATHAN M

  • Director
 0 2012-03-02 0

HARPER SEAN E

  • Director
 0 2012-03-02 0

DHINGRA KAPIL

  • Director
 0 2011-06-23 0

REISENAUER MARK L SVP, CHIEF COMMERCIAL OFFICER

  • Officer
 0 2011-03-16 0

BENJAMIN JERRY

  • Director
 0 2010-06-22 0

STAMPACCHIA OTELLO

  • Director
 2,197,413 2010-03-02 0

OMEGA FUND MANAGEMENT LTD

SIGMA HOLDING LTD

HELYAR CONNIE

ALVAREZ-MASTERTON SHARON ROSE

  • 10% Owner
 No longer subject to file 2009-08-04 0

OMEGA FUND MANAGEMENT LTD

SIGMA HOLDING LTD

STAMPACCHIA OTELLO

HELYAR CONNIE

ALVAREZ-MASTERTON SHARON ROSE

  • Director
  • 10% Owner
 4,577,313 2009-07-31 0

REINHARDT CARSTEN SVP & CMO

  • Officer
 0 2009-04-01 0

ZELM DONALD A CHIEF FINANCIAL OFFICER

  • Officer
 0 2008-05-01 0

ALVAREZ-MASTERTON SHARON ROSE

  • 10% Owner
 4,892,813 2008-01-14 0

SCHNEIDER PHILLIP M

  • Director
 22,500 2007-06-28 0

OMEGA FUND MANAGEMENT LTD

STAMPACCHIA OTELLO

HELYAR CONNIE

LUFF JOHN P

OMEGA FUND I, L.P.

OMEGA FUND GP, LTD.

OMEGA FUND III, L.P.

OMEGA FUND III GP, L.P.

OMEGA FUND III G.P., LTD.

SIGMA HOLDING LTD

  • Director
  • 10% Owner
 5,710,252 2007-06-22 0

SCHNITTKER CHRISTOPHER P CHIEF FINANCIAL OFFICER

  • Officer
 25,000 2007-06-10 0

LUFF JOHN P

  • 10% Owner
 3,257,936 2006-11-14 0

31 GROUP PLC

  • 10% Owner
 2,940,435 2006-05-05 0

ADVENT PRIVATE EQUITY FUND III A LTD PARTNERSHIP

ADVENT PRIVATE EQUITY FUND III B LTD PARTNERSHIP

ADVENT PRIVATE EQUITY FUND III C LTD PARTNERSHIP

ADVENT PRIVATE EQUITY FUND III D LTD PARTNERSHIP

ADVENT PRIVATE EQUITY FUND III GMBH & CO KG

ADVENT PRIVATE EQUITY FUND III AFFILIATES

ADVENT MANAGEMENT III L P

  • 10% Owner
 3,528,875 2006-05-05 0

OMEGA FUND I, L.P.

OMEGA FUND GP, LTD.

OMEGA FUND MANAGEMENT LTD

SIGMA HOLDING LTD

STAMPACCHIA OTELLO

HELYAR CONNIE

GUILLE ANDREW

  • Director
  • 10% Owner
 3,257,935 2006-05-05 0

MIROW GREGOR SVP, OPERATIONS

  • Officer
 0 2006-05-05 0

AKER HAZEL M SR. VP, GENERAL COUNSEL

  • Officer
 60,000 2006-03-27 0

LARUE WILLIAM R SR.VP AND CFO

  • Officer
 60,000 2006-03-27 0

GAMMON GUY VICE PRESIDENT, CLINICAL

  • Officer
 50,000 2006-03-27 0

VAN EPPS DENNIS E VP, RESEARCH

  • Officer
 50,000 2006-03-27 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

No recent transactions

*** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

Elevate your investments